Collagen Hybridizing Peptides allow for quantification of NASH Disease Activity

Collagen Remodeling Activity Significantly Higher in Faster Progressors of NAFLD/NASH.

Our In Vivo CHPs are conjugated with sCy 7.5 for near-IR detection. Contact us for customized conjugates.

Contact Us
Understanding Non-alcoholic Steatohepatitis (NASH)

Understanding nAMD

NASH is a type of nonalcoholic fatty liver disease(NAFLD), in which fat builds up in your liver. NASH induces inflammation and liver damage, along with fat in the liver. NASH is oftentimes a silent disease – with little to no apparent symptoms. In NASH, liver tissue is damaged to the point that it becomes replaced with scar tissue, a process known as fibrosis, which prevents the liver from working properly. NAFLD/NASH outcomes are challenging to predict due to the heterogeneity in disease progression.
Current Treatment Challenges
Currently, the only definitive method of diagnosing NASH is through a liver biopsy – which is invasive and painful. There are no FDA approved drugs to treat NASH, therefore there is nothing that can reverse fat buildup in the liver. As of now, the first line of management is simply lifestyle modifications: weight loss and increased physical activity.
Why CHPs?
CHP staining is an efficient prognostic for NASH progression. Staining remodeling collagen has displayed striking differences in fast versus slow progressors. Such CHP use will not only enable therapeutics through the FDA process, but also determine who should receive treatment once therapeutics are available.